ANI Pharmaceuticals (NASDAQ: ANIP) — Perfil da empresa, notícias e dados financeiros
ANI Pharmaceuticals develops and markets prescription pharmaceuticals, focusing on complex unmet medical needs across therapeutic areas.

ANI Pharmaceuticals
ANI Pharmaceuticals (NASDAQ:ANIP) is a specialized company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. At its core, ANI Pharmaceuticals strives to address complex challenges and unmet medical needs within the healthcare sector. The company's diverse project portfolio spans a range of therapeutic areas, including oncology, hormone therapy, and complex formulations. ANI is committed to delivering high-quality products that improve patient outcomes, emphasizing innovation in drug development and delivery. Major objectives for ANI Pharmaceuticals include expanding its product lineup through research and development, strategic acquisitions to enhance its market reach, and continued commitment to regulatory compliance and excellence in manufacturing. Through these endeavors, ANI aims to secure a significant position in the pharmaceutical industry by prioritizing patient care and shareholder value.
Resumo
Operações
Produtos e/ou serviços de ANI Pharmaceuticals
- Generic pharmaceuticals production, offering a wide range of medications across therapeutic areas.
- Branded pharmaceutical products, focusing on complex treatments in niche markets.
- Contract manufacturing services, providing comprehensive capabilities from development to commercialization.
- Pharmaceutical research and development, prioritizing innovative therapies and formulations.
- Drug distribution services, ensuring the efficient supply of medicines to healthcare providers.
- Regulatory support services, assisting partners through the drug approval process.
equipe executiva do ANI Pharmaceuticals
- Nikhil LalwaniPresident, CEO & Director
- Stephen P. CareySenior VP of Finance & CFO
- Meredith W. CookSenior VP, General Counsel & Corporate Secretary
- Christopher K. MutzSenior VP & Head of Rare Disease
- Ori GutwergSenior Vice President of Generics
- Muthusamy ShanmugamHead of R&D and COO of New Jersey Operations
- Irina Rivkind KofflerVice President of Investor Relations
- Elizabeth PowellChief Compliance Officer & Head of Legal of Rare Disease
- Chad GassertSenior Vice President of Corporate Development & Strategy
- Krista L. DavisSenior VP & Chief Human Resources Officer
Últimas notícias sobre a ANI Pharmaceuticals
ANI Pharmaceuticals eye implant trial meets endpoints
United StatesANI receives FDA approval for generic Everolimus
United StatesANI Pharmaceuticals revenue surges nearly 26%
United StatesANI Pharmaceuticals reports positive uveitis trial results
United StatesANI Pharmaceuticals surges on rare disease growth and raises 2026 outlook
United StatesANI Pharmaceuticals launches exclusive generic pimozide following FDA approval
United States
Principais indicadores financeiros
Resultados divulgados pela ANI Pharmaceuticals, em USD.
- Cap. de mercado
- 1,6 bi
- Receita (TTM)
- 978,4 mi
- P/L
- 15.4
- LPA (diluído, TTM)
- 4.6
- Dividend yield
- —
- Margem de lucro
- 11.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 883,4 mi | 81,2 mi | 78,3 mi | |
| 614,4 mi | 584 mil | -18,5 mi | |
| 486,8 mi | 47 mi | 18,8 mi | |
| 316,4 mi | -35,3 mi | -47,9 mi |